Results with Optune Gio
RESULTS WITH OPTUNE GIO
Proven to help people with newly diagnosed GBM live longer
The safety and efficacy of Optune Gio in people with newly diagnosed GBM was studied in a large, randomized clinical trial. This trial compared the effectiveness and safety of people treated with Optune Gio and chemotherapy to those treated with chemotherapy alone. In this study, those with newly diagnosed GBM who used Optune Gio in addition to chemotherapy had a greater chance to live longer than people who used chemotherapy alone.
Jeanneane, an Optune Gio user and Patient Ambassador, and Jenny, her care partner
WITH OPTUNE GIO + CHEMOTHERAPY*:
Nearly half of people using Optune Gio + chemotherapy were alive at 2 years
Compared with 31% of people using chemotherapy alone.
WITH OPTUNE GIO + CHEMOTHERAPY*:
Better survival at 5 years
13% of people using Optune Gio + chemotherapy were alive compared with 5% of people using chemotherapy alone.
WITH OPTUNE GIO + CHEMOTHERAPY*:
Tumor growth was delayed an average of 2.7 months longer
than in people using chemotherapy alone (6.7 months vs 4 months).
WITH OPTUNE GIO + CHEMOTHERAPY*:
On average, people lived 4.9 months longer
than those using chemotherapy alone (20.9 months vs 16 months).
WITH OPTUNE GIO + CHEMOTHERAPY*:
People maintained their quality of life
including mental, emotional, and physical health, for up to 12 months.
Craig, an Optune Gio user and Patient Ambassador
*Temozolomide, also known as TMZ or Temodar®.
Similar survival without chemotherapy-related side effects
In a large clinical study of people with recurrent GBM, Optune Gio was shown to have similar survival results to chemotherapy, without chemotherapy-related side effects.
WITH OPTUNE GIO
On average, people using Optune Gio lived an average of 6.6 months
while people on chemotherapy lived an average of 6 months.
People in the study reported better*:
*Results are based on change in quality of life from baseline to 3 months.